Q2 2024 EPS Estimates for OPKO Health, Inc. Decreased by HC Wainwright (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at HC Wainwright reduced their Q2 2024 earnings per share (EPS) estimates for shares of OPKO Health in a report released on Wednesday, May 8th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.40) EPS, Q1 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.33) EPS.

Other research analysts also recently issued research reports about the company. Barrington Research reaffirmed an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $5.00 price target on shares of OPKO Health in a research report on Monday, April 1st.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.28 on Monday. The firm has a market capitalization of $892.15 million, a price-to-earnings ratio of -3.66 and a beta of 1.81. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.91 and a quick ratio of 1.22. The business’s 50 day simple moving average is $1.15 and its 200-day simple moving average is $1.22. OPKO Health has a 12 month low of $0.85 and a 12 month high of $2.24.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The company had revenue of $173.70 million for the quarter, compared to analysts’ expectations of $182.99 million. During the same period in the prior year, the firm posted ($0.02) EPS. The firm’s quarterly revenue was down 26.9% on a year-over-year basis.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 1,000,000 shares of OPKO Health stock in a transaction that occurred on Wednesday, February 21st. The shares were purchased at an average cost of $0.99 per share, for a total transaction of $990,000.00. Following the completion of the transaction, the chief executive officer now owns 208,368,225 shares of the company’s stock, valued at approximately $206,284,542.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders acquired 3,100,000 shares of company stock worth $2,923,000. Insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently modified their holdings of the stock. Levin Capital Strategies L.P. boosted its holdings in OPKO Health by 30.0% in the third quarter. Levin Capital Strategies L.P. now owns 65,000 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 15,000 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of OPKO Health by 39.1% in the 3rd quarter. Principal Financial Group Inc. now owns 59,566 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 16,733 shares in the last quarter. Capula Management Ltd lifted its stake in shares of OPKO Health by 45.0% in the 3rd quarter. Capula Management Ltd now owns 540,540 shares of the biotechnology company’s stock valued at $865,000 after purchasing an additional 167,860 shares in the last quarter. Barclays PLC grew its holdings in shares of OPKO Health by 17.4% during the 3rd quarter. Barclays PLC now owns 188,421 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 27,946 shares during the period. Finally, Swiss National Bank increased its position in OPKO Health by 1.0% during the 3rd quarter. Swiss National Bank now owns 934,055 shares of the biotechnology company’s stock worth $1,494,000 after purchasing an additional 8,800 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.